The statement below was issued on 12 March 2015:
In addition to today’s news of continued expansion into the Asian market, Admedus announced that it is on track for the strongest quarter of CardioCel® sales, building on the foundation of key, global centre use that has been established over the past year."
|Given that the revenue for the 2nd quarter was $2.5 million, then if the above statement was correct, then sales of other products have declined significantly as the receipts were approximately $400k under the 2nd quarter with revenue static. No surprise that the market reacted with a 3.8% decrease.
The company owes its shareholders more frequent updates on the revenues and the breakdown of the revenue figures.
Quarterly, page-84
-
- There are more pages in this discussion • 91 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$17.91 |
Change
-0.090(0.50%) |
Mkt cap ! $344.2M | |||
| Open | High | Low | Value | Volume |
| $18.00 | $18.10 | $17.75 | $74.32K | 4.151K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 681 | $17.90 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $18.25 | 100 | 1 |
View Market Depth
| Last trade - 16.10pm 15/07/2024 (20 minute delay) ? |
| AVR (ASX) Chart |